动理学磁带对健康狗的步态变异性的影响
Ching-Ming Liu1, Syu-Lun Lin1, Hsiao-Man Liu2
1National Taiwan University Veterinary Hospital, Taipei City, Taiwan.
Frontiers in veterinary science
|December 25, 2025
概括
狗的动理学录音显示,对步态变化的影响很小,不同方法的结果不一致. 毛发的存在对狗的生物力学有适度的影响.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 生物机械研究 生物机械研究
- 狗体育医学 狗体育医学
背景情况:
- 运动学磁带被广泛用于人类和马类运动和康复.
- 有限的研究存在于它的应用和狗的影响.
- 了解狗的生物力学对于优化性能和恢复至关重要.
研究的目的:
- 为了研究运动学磁带对健康狗的步态变异性的影响.
- 评估不同带方法对狗的移动性和步态参数的影响.
- 为了探索潜在的神经肌肉对狗皮肤刺激的反应.
主要方法:
- 八只健康的客户拥有的狗参与了这项研究.
- 三种不同的动理学带方法被应用到双腿骨肌肌.
- 使用姿势分析仪和压力敏感路径,以及移动性和姿势评估,进行了步行分析.
主要成果:
- 动理学磁带显示,对健康狗的整体运动和姿势的影响很小.
- 动力和时空步行参数的只有一个小小的子集 (在29个中只有3个) 显示出了统计学上显著的差异.
- 这些效应在各种贴带方法之间不一致,并且受应用部位上毛发的存在或不存在的影响.
结论:
- 动理学磁带似乎对健康狗的步态变量有轻微和不一致的影响.
- 毛发的存在可以适度地影响犬体内运动学录像的结果.
- 这项研究为未来对犬神经肌肉调节和步态生物力学的研究提供了基础数据.
相关概念视频
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


